Organon & Co
About: Organon & Co is a science-based global pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. The Company's operations include the following product portfolio: Women's health, Biosimilars, and Established medicines. Geographically, it derives a majority of its revenue from Europe and Canada followed by the United States and then Asia Pacific and Japan. The company generates the majority of its revenue from the Established Brands product portfolio.
Employees: 10,000
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
59% more call options, than puts
Call options by funds: $36M | Put options by funds: $22.7M
9% more first-time investments, than exits
New positions opened: 89 | Existing positions closed: 82
1% less funds holding
Funds holding: 714 [Q2] → 708 (-6) [Q3]
2.5% less ownership
Funds ownership: 79.52% [Q2] → 77.02% (-2.5%) [Q3]
10% less capital invested
Capital invested by funds: $4.23B [Q2] → $3.79B (-$442M) [Q3]
14% less funds holding in top 10
Funds holding in top 10: 7 [Q2] → 6 (-1) [Q3]
15% less repeat investments, than reductions
Existing positions increased: 209 | Existing positions reduced: 247
Research analyst outlook
We haven’t received any recent analyst ratings for OGN.
Financial journalist opinion
Based on 6 articles about OGN published over the past 30 days
